Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells

[1]  M. Hedger,et al.  Toll‐like receptors in the gonads and reproductive tract: emerging roles in reproductive physiology and pathology , 2007, Immunology and cell biology.

[2]  E. Wiemer.  The role of microRNAs in cancer: no small matter. , 2007, European journal of cancer.

[3]  S. Akira,et al.  Identification of a key pathway required for the sterile inflammatory response triggered by dying cells , 2007, Nature Medicine.

[4]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[5]  H. Xiong,et al.  Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. , 2007, Cancer research.

[6]  Nan Li,et al.  TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. , 2007, Molecular immunology.

[7]  R. Chen,et al.  Inflammation, Cancer and Chemoresistance: Taking Advantage of the Toll‐Like Receptor Signaling Pathway , 2007, American journal of reproductive immunology.

[8]  David Baltimore,et al.  MicroRNA-155 is induced during the macrophage inflammatory response , 2007, Proceedings of the National Academy of Sciences.

[9]  J. Nadel,et al.  Pseudomonas Lipopolysaccharide Accelerates Wound Repair via Activation of a Novel Epithelial Cell Signaling Cascade1 , 2006, The Journal of Immunology.

[10]  R. Chen,et al.  MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer , 2006, The Yale journal of biology and medicine.

[11]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[12]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[13]  R. Chen,et al.  TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. , 2006, Cancer research.

[14]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[15]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Mor,et al.  Molecular mechanism of phenoxodiol‐induced apoptosis in ovarian carcinoma cells , 2006, Cancer.

[17]  M. Tsan.  Toll-like receptors, inflammation and cancer. , 2006, Seminars in cancer biology.

[18]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[19]  C. Croce,et al.  The role of microRNA genes in papillary thyroid carcinoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Prestwich,et al.  Regulation of lung injury and repair by Toll-like receptors and hyaluronan , 2005, Nature Medicine.

[21]  Alexander Hoffmann,et al.  Stimulus Specificity of Gene Expression Programs Determined by Temporal Control of IKK Activity , 2005, Science.

[22]  D. Baltimore,et al.  Achieving Stability of Lipopolysaccharide-Induced NF-κB Activation , 2005, Science.

[23]  Yibang Chen,et al.  Toll-like receptors on tumor cells facilitate evasion of immune surveillance. , 2005, Cancer research.

[24]  J. Andersen,et al.  TLR11 Activation of Dendritic Cells by a Protozoan Profilin-Like Protein , 2005, Science.

[25]  I. Verma,et al.  Inflammation-associated cancer: NF-κB is the lynchpin , 2005 .

[26]  R. Xu,et al.  Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[27]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[28]  Masakazu Toi,et al.  Nuclear factor-κB inhibitors as sensitizers to anticancer drugs , 2005, Nature Reviews Cancer.

[29]  Wayne Tam,et al.  Accumulation of miR-155 and BIC RNA in human B cell lymphomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Tomai,et al.  Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 , 2005, The Journal of Immunology.

[31]  Jason M Doherty,et al.  Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Schreiber,et al.  Inflammation as a tumor promoter in cancer induction. , 2004, Seminars in cancer biology.

[33]  A. Schaeffer.  A Toll-Like Receptor That Prevents Infection by Uropathogenic Bacteria , 2004 .

[34]  P. Beachy,et al.  Mending and malignancy , 2004, Nature.

[35]  L. Coussens,et al.  Cancer: An inflammatory link , 2004, Nature.

[36]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[37]  S. Nilsson,et al.  Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies , 2004, Acta obstetricia et gynecologica Scandinavica.

[38]  Peter Scheurich,et al.  NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP , 2004, The Journal of cell biology.

[39]  Ruslan Medzhitov,et al.  Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis , 2004, Cell.

[40]  T. Okai,et al.  Malignant transformation of endometriosis: application of laser microdissection for analysis of genetic alterations according to pathological changes , 2004, Medical Electron Microscopy.

[41]  R. Medzhitov,et al.  Toll signaling: RIPping off the TNF pathway , 2004, Nature Immunology.

[42]  Yves Pommier,et al.  Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks , 2004, Oncogene.

[43]  S. Akira,et al.  Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 , 2004, Science.

[44]  Shizuo Akira,et al.  TLR signaling pathways. , 2004, Seminars in immunology.

[45]  Shizuo Akira,et al.  Toll/IL-1 Receptor Domain-Containing Adaptor Inducing IFN-β (TRIF) Associates with TNF Receptor-Associated Factor 6 and TANK-Binding Kinase 1, and Activates Two Distinct Transcription Factors, NF-κB and IFN-Regulatory Factor-3, in the Toll-Like Receptor Signaling 1 , 2003, The Journal of Immunology.

[46]  S. Akira,et al.  Role of adapters in Toll-like receptor signalling. , 2003, Biochemical Society transactions.

[47]  G. Mor,et al.  Phenoxodiol – an isoflavone analog – induces apoptosis in chemoresistant ovarian cancer cells , 2003, Oncogene.

[48]  G. Mor,et al.  Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis. , 2002, Biochemical pharmacology.

[49]  C. Bucana,et al.  Lipopolysaccharide‐induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion , 2002, International journal of cancer.

[50]  I. Gannot,et al.  Increase in immune cell infiltration with progression of oral epithelium from hyperkeratosis to dysplasia and carcinoma , 2002, British Journal of Cancer.

[51]  M. Shlomchik,et al.  Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.

[52]  L. O’Neill,et al.  Ras Participates in the Activation of p38 MAPK by Interleukin-1 by Associating with IRAK, IRAK2, TRAF6, and TAK-1* , 2002, The Journal of Biological Chemistry.

[53]  Bharat B. Aggarwal,et al.  Nuclear Factor-κB Activation: A Question of Life or Death , 2002 .

[54]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[55]  S. Crowe,et al.  Helicobacter pylori Infection as a Model for Gastrointestinal Immunity and Chronic Inflammatory Diseases , 2001, Digestive Diseases.

[56]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[57]  H. Redmond,et al.  The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease , 1999, British Journal of Cancer.

[58]  N. Harada,et al.  Macrophages, estrogen and the microenvironment of breast cancer , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[59]  F. Martinon,et al.  MyD88, an Adapter Protein Involved in Interleukin-1 Signaling* , 1998, The Journal of Biological Chemistry.

[60]  G. Hardiman,et al.  A family of human receptors structurally related to Drosophila Toll. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Z. Cao,et al.  MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. , 1997, Immunity.

[62]  P. Feng,et al.  IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. , 1997, Science.

[63]  S. Ménard,et al.  Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  W. S. Hayward,et al.  bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA , 1997, Molecular and cellular biology.

[65]  S. Kennedy.  Endometriosis , 1992, The Lancet.

[66]  R. Virchow.  Reizung und Reizbarkeit , 1858, Archiv für pathologische Anatomie und Physiologie und für klinische Medicin.

[67]  T. Rana,et al.  Illuminating the silence: understanding the structure and function of small RNAs , 2007, Nature Reviews Molecular Cell Biology.

[68]  David Baltimore,et al.  Achieving stability of lipopolysaccharide-induced NF-kappaB activation. , 2005, Science.

[69]  M. Toi,et al.  Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. , 2005, Nature reviews. Cancer.

[70]  I. Verma,et al.  Inflammation-associated cancer: NF-kappaB is the lynchpin. , 2005, Trends in immunology.

[71]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[72]  Rinat Abramovitch,et al.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.

[73]  S. Akira,et al.  Toll-like receptors. , 2003, Annual review of immunology.

[74]  P. Schwartz.  Current diagnosis and treatment modalities for ovarian cancer. , 2002, Cancer treatment and research.

[75]  Shishir Shishodia,et al.  Nuclear factor-kappaB activation: a question of life or death. , 2002, Journal of biochemistry and molecular biology.

[76]  G. Ruvkun.  Molecular biology. Glimpses of a tiny RNA world. , 2001, Science.

[77]  G. Mor,et al.  Apoptosis and apoptosis-related proteins (Fas, Fas ligand, Blc-2, p53) in lymphoid elements of human ovarian tumors. , 2000, European journal of gynaecological oncology.

[78]  G. Mor,et al.  Apoptosis and apoptosis-related proteins (Fas, Fas ligand, bcl-2, p53) in macrophages of human ovarian epithelial tumors. , 2000, European journal of gynaecological oncology.

[79]  R. Virchow,et al.  Die krankhaften Geschwülste , 1978 .

[80]  J. Dahlberg,et al.  Molecular biology. , 1977, Science.

[81]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.